vs

Side-by-side financial comparison of MEDIFAST INC (MED) and NewtekOne, Inc. (NEWT). Click either name above to swap in a different company.

MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $73.3M, roughly 1.0× NewtekOne, Inc.). On growth, NewtekOne, Inc. posted the faster year-over-year revenue change (-2.7% vs -36.9%). MEDIFAST INC produced more free cash flow last quarter ($-6.6M vs $-579.3M). Over the past eight quarters, NewtekOne, Inc.'s revenue compounded faster (12.2% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

NewTek, Inc., is a hardware and software company, based in San Antonio, Texas, that produced live and post-production video tools and visual imaging software for personal computers. The company was founded in 1985 in Topeka, Kansas, United States, by Tim Jenison and Paul Montgomery. On April 1, 2019, it was announced that NewTek would be acquired by Vizrt.

MED vs NEWT — Head-to-Head

Bigger by revenue
MED
MED
1.0× larger
MED
$75.1M
$73.3M
NEWT
Growing faster (revenue YoY)
NEWT
NEWT
+34.2% gap
NEWT
-2.7%
-36.9%
MED
More free cash flow
MED
MED
$572.7M more FCF
MED
$-6.6M
$-579.3M
NEWT
Faster 2-yr revenue CAGR
NEWT
NEWT
Annualised
NEWT
12.2%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MED
MED
NEWT
NEWT
Revenue
$75.1M
$73.3M
Net Profit
$19.5M
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
111.8%
Revenue YoY
-36.9%
-2.7%
Net Profit YoY
6.6%
EPS (diluted)
$-1.64
$0.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
NEWT
NEWT
Q4 25
$75.1M
$73.3M
Q3 25
$89.4M
$74.9M
Q2 25
$105.6M
$70.2M
Q1 25
$115.7M
$66.3M
Q4 24
$119.0M
$75.4M
Q3 24
$140.2M
$62.8M
Q2 24
$168.6M
$61.1M
Q1 24
$174.7M
$58.3M
Net Profit
MED
MED
NEWT
NEWT
Q4 25
$19.5M
Q3 25
$-2.3M
$17.9M
Q2 25
$2.5M
$13.7M
Q1 25
$-772.0K
$9.4M
Q4 24
$18.3M
Q3 24
$1.1M
$11.9M
Q2 24
$-8.2M
$10.9M
Q1 24
$8.3M
$9.7M
Gross Margin
MED
MED
NEWT
NEWT
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
MED
MED
NEWT
NEWT
Q4 25
-10.4%
Q3 25
-4.6%
Q2 25
-1.0%
Q1 25
-1.1%
Q4 24
0.6%
Q3 24
1.5%
Q2 24
-4.7%
Q1 24
4.5%
Net Margin
MED
MED
NEWT
NEWT
Q4 25
111.8%
Q3 25
-2.5%
23.9%
Q2 25
2.3%
19.5%
Q1 25
-0.7%
14.1%
Q4 24
24.3%
Q3 24
0.8%
19.0%
Q2 24
-4.8%
17.9%
Q1 24
4.8%
16.6%
EPS (diluted)
MED
MED
NEWT
NEWT
Q4 25
$-1.64
$0.64
Q3 25
$-0.21
$0.67
Q2 25
$0.22
$0.52
Q1 25
$-0.07
$0.35
Q4 24
$0.08
$0.70
Q3 24
$0.10
$0.45
Q2 24
$-0.75
$0.43
Q1 24
$0.76
$0.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
NEWT
NEWT
Cash + ST InvestmentsLiquidity on hand
$167.3M
Total DebtLower is stronger
$819.9M
Stockholders' EquityBook value
$198.9M
$397.6M
Total Assets
$248.0M
$2.7B
Debt / EquityLower = less leverage
2.06×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
NEWT
NEWT
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
Q3 24
$170.0M
Q2 24
$163.5M
Q1 24
$156.4M
Total Debt
MED
MED
NEWT
NEWT
Q4 25
$819.9M
Q3 25
$748.5M
Q2 25
$657.3M
Q1 25
$774.0M
Q4 24
$708.0M
Q3 24
$655.8M
Q2 24
$652.0M
Q1 24
$662.5M
Stockholders' Equity
MED
MED
NEWT
NEWT
Q4 25
$198.9M
$397.6M
Q3 25
$214.7M
$386.7M
Q2 25
$216.0M
$312.2M
Q1 25
$211.0M
$302.3M
Q4 24
$210.1M
$296.3M
Q3 24
$207.3M
$281.8M
Q2 24
$205.3M
$274.0M
Q1 24
$211.0M
$254.1M
Total Assets
MED
MED
NEWT
NEWT
Q4 25
$248.0M
$2.7B
Q3 25
$268.2M
$2.4B
Q2 25
$269.3M
$2.1B
Q1 25
$280.0M
$2.1B
Q4 24
$284.2M
$2.1B
Q3 24
$291.2M
$1.7B
Q2 24
$293.5M
$1.6B
Q1 24
$302.8M
$1.5B
Debt / Equity
MED
MED
NEWT
NEWT
Q4 25
2.06×
Q3 25
1.94×
Q2 25
2.11×
Q1 25
2.56×
Q4 24
2.39×
Q3 24
2.33×
Q2 24
2.38×
Q1 24
2.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
NEWT
NEWT
Operating Cash FlowLast quarter
$-5.3M
$-579.2M
Free Cash FlowOCF − Capex
$-6.6M
$-579.3M
FCF MarginFCF / Revenue
-8.8%
-790.0%
Capex IntensityCapex / Revenue
1.8%
0.1%
Cash ConversionOCF / Net Profit
-29.64×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$-1.0B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
NEWT
NEWT
Q4 25
$-5.3M
$-579.2M
Q3 25
$12.1M
$-167.3M
Q2 25
$-3.4M
$-199.8M
Q1 25
$3.4M
$-60.7M
Q4 24
$-4.9M
$-153.0M
Q3 24
$9.1M
$-25.7M
Q2 24
$13.1M
$2.9M
Q1 24
$7.3M
$-38.7M
Free Cash Flow
MED
MED
NEWT
NEWT
Q4 25
$-6.6M
$-579.3M
Q3 25
$10.8M
$-167.3M
Q2 25
$-4.8M
$-199.9M
Q1 25
$1.9M
$-60.7M
Q4 24
$-7.2M
$-153.5M
Q3 24
$7.7M
$-25.9M
Q2 24
$11.1M
$2.9M
Q1 24
$5.4M
$-38.7M
FCF Margin
MED
MED
NEWT
NEWT
Q4 25
-8.8%
-790.0%
Q3 25
12.0%
-223.3%
Q2 25
-4.5%
-284.7%
Q1 25
1.6%
-91.6%
Q4 24
-6.1%
-203.6%
Q3 24
5.5%
-41.2%
Q2 24
6.6%
4.7%
Q1 24
3.1%
-66.5%
Capex Intensity
MED
MED
NEWT
NEWT
Q4 25
1.8%
0.1%
Q3 25
1.5%
0.0%
Q2 25
1.3%
0.1%
Q1 25
1.3%
0.1%
Q4 24
1.9%
0.6%
Q3 24
1.0%
0.4%
Q2 24
1.1%
0.1%
Q1 24
1.1%
0.1%
Cash Conversion
MED
MED
NEWT
NEWT
Q4 25
-29.64×
Q3 25
-9.35×
Q2 25
-1.36×
-14.58×
Q1 25
-6.48×
Q4 24
-8.35×
Q3 24
8.04×
-2.15×
Q2 24
0.27×
Q1 24
0.88×
-4.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons